NCT02234596 - Nintedanib in Patients With Advanced Esophagogastric Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 4, 2014

Primary Completion Date

April 22, 2020

Study Completion Date

April 22, 2020

Conditions

Esophagogastric Adenocarcinoma

Interventions

DRUG

Nintedanib

Nintedanib 200mg twice daily administered continuously. Patients will continue on treatment until progression of disease. Each cycle consists of 28 days continuously, unless interrupted for intolerable toxicity.

Trial Locations (6)

10065

Memorial Sloan Kettering Cancer Center 1275 York Avenue, New York

10604

Memorial Sloan Kettering Westchester, Harrison

11725

Memorial Sloan Kettering Cancer Center @ Suffolk, Commack

Unknown

Memoral Sloan Kettering Cancer Center, Basking Ridge

Memorial Sloan Kettering at Mercy Medical Center, Rockville Centre

07748

Memorial Sloan Kettering Monmouth, Middletown

All Listed Sponsors

lead

Memorial Sloan Kettering Cancer Center

OTHER